First European Patients Commence Dosing in Lupuzor’s™ Pivotal Phase III Study

7th June 2016 - 2:06 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease.

ImmuPharma is pleased to confirm that the first European sites opened have now commenced dosing Lupus patients. Recruitment in this pivotal Phase III study for Lupuzor™ will occur in up to 45 investigator sites. 10 sites in United States and 35 in Europe.

Further updates on the progression of the Lupuzor™ Phase III trial will be announced, as appropriate, as the trial progresses. Progress on the trial can also be seen at:

Commenting on the event, Tim McCarthy, Chairman, said: “This a further key milestone for ImmuPharma’s Lupuzor™ trial with now both the US and European sites dosing Lupus patients. We look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses throughout this year and 2017.”

Lupuzor™ Symposium on 8 & 9 June : Key Presenter : Prof. Sylviane Muller

As recently confirmed, a Lupuzor™ Symposium is being hosted this week with Prof. Muller, inventor of Lupuzor™ presenting on the unique ‘Mechanism of Action’ of Lupuzor™, also known by its chemical name ‘Forigerimod’ or ‘P140’. Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.

For more information or if you would like to attend one of the briefings, please email: A video of the presentation will be available on the Company’s website from Monday 13 June on:

Share this article